INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Condition(s) studied
Investigational drug(s) / intervention(s)
INO-5401: INO-5401 is a combination of 3 separate DNA plasmids targeting Wilms tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) genes. Starting on Day 0 three milligrams (mg) of each plasmid will be delivered IM followed by EP using the CELLECTRA® 2000 EP device every three weeks for four doses, and then every 9 weeks until disease progression as defined by immunotherapy Response Assessment in Neuro-Oncology (iRANO), unacceptable toxicity, withdrawal of consent, or death.
INO-9012: INO-9012 is a DNA plasmid for expression of human interleukin-12 (IL-12). Starting on Day 0 one mg plasmid will be delivered IM followed by EP using the CELLECTRA® 2000 EP device every three weeks for four doses, and then every 9 weeks until disease progression as defined by iRANO, unacceptable toxicity, withdrawal of consent, or death.
Cemiplimab: Cemiplimab is an antibody to programmed death-1 (PD-1) protein. Starting on Day 0 cemiplimab will be administered intravenously (IV) every three weeks at a dose of 350 mg per dose in the absence of dose holding, until disease progression as defined by iRANO, unacceptable toxicity, withdrawal of consent, or death.
Radiation Therapy: Radiation therapy (RT) will begin no later than 42 days after surgical intervention, and should start approximately 2 weeks after Day 0. RT will be given for three weeks.
Temozolomide: Temozolomide (TMZ) will be given daily during radiation therapy (RT) at a dose of 75 milligrams per square meter (mg/m\^2).
Study summary
Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM).
Eligibility
Primary outcome measure(s)
- Percentage of Participants with Adverse Events (AEs) — From Day 0 to 30 days after the last dose of study treatment (non-serious AEs) and to 6 months after the last dose of study treatment (immune-related AEs, AEs of special interest and serious AEs) up to approximately 24 months
Trial sites (21)
| Facility | City | Region | Status |
|---|---|---|---|
| City of Hope | Duarte | California | |
| Stanford University, School of Medicine | Palo Alto | California | |
| University of California, San Francisco | San Francisco | California | |
| University of Miami - Sylvester Comprehensive Cancer Center | Miami | Florida | |
| Moffitt Cancer Center | Tampa | Florida | |
| Emory University School of Medicine | Atlanta | Georgia | |
| Dana-Farber Cancer Institute | Boston | Massachusetts | |
| Henry Ford Health System | Detroit | Michigan | |
| Rutgers University - Cancer Institute of New Jersey | New Brunswick | New Jersey | |
| New York University Langone Medical Center; Perlmutter Cancer Center | New York | New York | |
| Icahn School of Medicine at Mount Sinai | New York | New York | |
| Columbia University Medical Center The Neurological Institute of New York | New York | New York | |
| New York-Presbyterian Hospital/Weill Cornell Medical Center | New York | New York | |
| University of North Carolina School of Medicine | Chapel Hill | North Carolina | |
| Stephenson Cancer Center | Oklahoma City | Oklahoma | |
| Oregon Health & Science University | Portland | Oregon | |
| University of Pennsylvania Health System: Penn Medicine | Philadelphia | Pennsylvania | |
| UPMC Cancer Center Neuro-Oncology; UPMC Cancer Pavilion | Pittsburgh | Pennsylvania | |
| Texas Oncology | Austin | Texas | |
| Baylor College of Medicine | Houston | Texas | |
| Huntsman Cancer Institute | Salt Lake City | Utah |
On this site
📄 Libtayo (cemiplimab) drug profile →Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT03491683 on ClinicalTrials.gov ↗ ← All trials in the USA